DGX Quest Diagnostics: Price-to-Projected Revenue Ratio

Corporate emblem and logo of questdiagnostics.com (DGX)

Quest Diagnostics diversifies risks through a broad spectrum of testing, ranging from routine screenings to complex genetics, while disciplined management focuses on rigorous execution and the molecular segment. The expected P/S valuation reconciles these approaches, with 2.10 serving as the current level of the metric. Ultimately, automated patient routing and laboratory scale transform the business into a stable healthcare cash cow.

DGX (Quest Diagnostics Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

Quest Corp - analytical breakdowns and key metrics (DGX)

- current price and projected stock value:
Stock Price Quest Diagnostics Incorporated|DGX - Average Forecast Price
- company stock capitalization data:
Market Value Quest Corp|DGX - Company Buyout Price
- book value of equity indicators:
Accounting Value per Share Quest Diagnostics|DGX - Total Net Assets|Market Cap to Net Assets Ratio questdiagnostics.com|DGX - Aggregate Asset Value
- company liabilities and liquidity data:
Total Debt to Capital Quest Diagnostics|DGX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Quest Diagnostics|DGX - Company Total Debt Obligations|Debts to Book Capitalization Quest Corp|DGX - Company Long-Term Debts|Company Short-Term Debts Quest Diagnostics|Quick Liquidity questdiagnostics.com
- net income and valuation multiples indicators:
DGX - Company Profit|Expected Profit Quest Diagnostics|DGX - Market Cap to Earnings|Future Price to Earnings Quest|DGX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Quest Corp|DGX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Quest Diagnostics|DGX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth questdiagnostics.com|DGX - Net earnings per share growth this year|Net earnings per share growth forecast for next year Quest Diagnostics
- issuer revenue and sales details:
DGX - Company Gross Revenue|Projected Sales Volume Quest Diagnostics Incorporated|DGX - Market Cap to Revenue Ratio|Forward P/S Multiple Quest Corp
Comprehensive company analysis:Quest Diagnostics Incorporated DGX
Product sample of Quest Corp

Fundamental risks for Quest Diagnostics (DGX) are mitigated through an analysis of the market capitalization to expected revenue ratio. For a business providing critical diagnostic infrastructure in the US, this metric confirms the fair value of assets amid market maturity. The trend of the forward P/S multiple allows for the filtering of speculative noise, assessing the current price as a result of discounting the company's future cash flows.

Competitors of Quest Diagnostics

Forward P/S Multiple A (Agilent)|Illumina Inc (ILMN) - Market Cap to Future Revenue Ratio|EXAS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Revvity Corp RVTY|BIO (Bio-Rad Laboratories) - Forward Price-to-Revenue Multiple|NNNN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple SHC|QDEL: Forward Price to Sales|Forward P/S Multiple OPK|CareDx Health - Market Cap to Projected Revenue|Forward P/S Multiple MRVI (Maravai LifeSciences)|Market Cap to Expected Sales Ratio fulgentgenetics.com (FLGT)|Standard BioTools - Forward P/S Multiple|CTKB - Forward P/S Multiple|OSUR: Forward P/S Multiple|Projected Price to Revenue Exagen XGN|Price-to-Projected Revenue Ratio MDxHealth SA|Market Cap to Projected Revenue LUCD (luciddx.com)|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|IMDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Trinity Biotech TRIB|Market Cap to Expected Sales Ratio ProPhase Labs Corp (PRPH)|AIMD: Forward Price-to-Revenue Multiple|codiagnostics.com - Price to Expected Revenue Ratio|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|CDIO (Cardio Diagnostics Holdings Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Onconetix Corporation (ONCO)|Price-to-Projected Revenue Ratio Virax Biolabs Group (VRAX)|Market Cap to Expected Sales Ratio bluejaydx.com|Forward P/S Multiple AWH (Aspira Women's Health Inc.)|AXDX: Market Cap to Projected Revenue|centogene.com - Forward P/S Multiple|Projected Price to Revenue Enzo Biochem, Inc. (ENZ)|FRES (fresh2.co) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue GENE|Price-to-Projected Revenue Ratio 23andMe|Forward Price-to-Revenue Multiple Psychemedics Corp. (PMD)